Meanwhile, nivolumab monotherapy (three mg/kg/2 weeks) only achieved an ORR of 4% in another trial in which 17(68%) of 25 patients had a PD-L1-positive tumor (Santin et al., 2020). Here, CD274 is linked to neoplasm.